0001328143-19-000055.txt : 20191231 0001328143-19-000055.hdr.sgml : 20191231 20191125175430 ACCESSION NUMBER: 0001328143-19-000055 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20191125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-3554 MAIL ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 CORRESP 1 filename1.htm Document


ADAMAS PHARMACEUTICALS, INC.
1900 Powell Street, Suite 1000
Emeryville, CA 94608
(510) 450-3500


November 25, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ada D. Sarmento
Joe McCann
RE:
Adamas Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-234570
Ladies and Gentlemen:
Adamas Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on December 2, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

Very truly yours,
Adamas Pharmaceuticals, Inc.

By: /s/ Christopher B. Prentiss    
Christopher B. Prentiss
Chief Financial Officer